首页> 美国卫生研究院文献>Clinical and Experimental Immunology >Evaluation of serum levels of tumour necrosis factor-alpha (TNF-alpha) and soluble IL-2 receptor (sIL-2R) and CD4 CD8 and natural killer (NK) populations during infrared pulsed laser device (IPLD) treatment.
【2h】

Evaluation of serum levels of tumour necrosis factor-alpha (TNF-alpha) and soluble IL-2 receptor (sIL-2R) and CD4 CD8 and natural killer (NK) populations during infrared pulsed laser device (IPLD) treatment.

机译:在红外脉冲激光设备(IPLD)治疗期间评估血清肿瘤坏死因子-α(TNF-alpha)和可溶性IL-2受体(sIL-2R)以及CD4CD8和自然杀伤(NK)人群的血清水平。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The purpose of this study was to evaluate serum levels of TNF-alpha, sIL-2R and distribution of peripheral leucocyte subsets in patients with advanced neoplastic disease undergoing IPLD treatment. Fifteen cancer patients with evidence of persistent disease were further divided in two groups according to outcome at the end of the period of clinical evaluation: group 1 patients were still alive and group 2 patients had died. Our results show: (i) an increase in the initial level of TNF-alpha in both groups; (ii) a decrease in TNF-alpha levels during the follow up of group 1 patients; (iii) a significant increase in serum levels of sIL-2R in patients in group 2 compared with those in group 1; (iv) a progressive and constant increase in TNF-alpha levels in group 2; (v) a decrease in CD4+CD45RA+ subpopulation in both groups; (vi) an increase in CD25+ cells; (vii) an increase in CD4+, CD4+CD45RA+ and CD25+ cells during the follow up of group 2 patients. The data generated here form the basis for further investigations on the use of IPLD as a single agent and in combination with other biological response modifiers in cancer patients.
机译:这项研究的目的是评估接受IPLD治疗的晚期肿瘤病患者的血清TNF-α,sIL-2R水平和外周血白细胞亚群的分布。在临床评估期结束时,根据结果将15例具有持续性疾病证据的癌症患者进一步分为两组:第1组患者仍然活着,第2组患者死亡。我们的结果表明:(i)两组中TNF-α的初始水平均增加; (ii)在第1组患者的随访期间TNF-α水平降低; (iii)与第1组相比,第2组患者的sIL-2R血清水平显着升高; (iv)第2组中TNF-α水平的持续升高; (v)两组中CD4 + CD45RA +亚群的减少; (vi)CD25 +细胞的增加; (vii)在第2组患者的随访期间CD4 +,CD4 + CD45RA +和CD25 +细胞增加。此处生成的数据构成了进一步研究将IPLD作为单一药物并与其他生物反应调节剂联合用于癌症患者的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号